Who is CSL?
CSL Limited is a global biotechnology company that develops, manufactures, and distributes plasma-derived and recombinant biotherapies and vaccines for serious and rare diseases.
- Plasma-derived biotherapies, including immunoglobulins, albumin, and clotting factor concentrates
- Seasonal influenza vaccine development and manufacturing
- Recombinant protein therapeutics produced in mammalian cell expression systems
- Large-scale plasma collection, fractionation, and purification operations
- Research in rare blood disorders, immunology, and cardiovascular conditions
Show more
More About CSL
CSL's biotherapies business centers on plasma collection and fractionation, producing immunoglobulins, albumin, and clotting factor concentrates used in hospitals and specialty care settings. Healthcare system buyers typically procure these products through hospital pharmacy and specialty distribution channels, where supply continuity, quality assurance, and regulatory compliance are central considerations in adoption.
The company's manufacturing depends on large-scale plasma fractionation, cell culture, and purification processes. These operations are governed by good manufacturing practice standards overseen by regulators such as the United States Food and Drug Administration and the Therapeutic Goods Administration in Australia. Cold chain logistics and quality management systems are significant operational factors across its product portfolio.
CSL's recombinant therapeutics rely on mammalian cell expression platforms, which allow production of complex protein molecules at commercial scale. The company also maintains a vaccines operation focused on seasonal influenza prevention, extending its manufacturing footprint beyond plasma-derived products.
In plasma-derived therapies, CSL competes with other large producers in the immunoglobulin and clotting factor categories, including Grifols and Takeda. Its position reflects a combination of plasma sourcing scale, fractionation capacity, and a broad specialty therapy portfolio, which supports long-term supply relationships with healthcare providers.
Business significance lies in the continuity of supply for treatments of primary immune deficiencies, bleeding disorders, and other rare conditions where alternative therapies are limited. CSL is listed on the Australian Securities Exchange and is headquartered in Melbourne, Australia. Its directory positioning reflects current solution areas in plasma biotherapeutics, vaccines, and recombinant therapies within the biotechnology and life sciences segment of health care.
Our description of CSL. Updated October 2026.
